These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3436066

  • 1. Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
    Allain P, Chaleil D, Mauras Y, Beaudeau G, Varin MC, Poignet JL, Ciancioni C, Ang KS, Cam G, Simon P.
    Clin Chim Acta; 1987 Dec; 170(2-3):331-8. PubMed ID: 3436066
    [Abstract] [Full Text] [Related]

  • 2. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H, Stummvoll HK, Meisinger V.
    Proc Eur Dial Transplant Assoc; 1981 Dec; 18():674-80. PubMed ID: 7329995
    [Abstract] [Full Text] [Related]

  • 3. Concomitant removal of aluminium and iron by haemodialysis and haemofiltration after desferrioxamine intravenous infusion.
    Ciancioni C, Poignet JL, Naret C, Delons S, Mauras Y, Allain P, Man NK.
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985 Dec; 21():469-73. PubMed ID: 3991542
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of desferrioxamine and of its iron and aluminum chelates in patients on peritoneal dialysis.
    Allain P, Chaleil D, Mauras Y, Varin MC, Ang KS, Cam G, Simon P.
    Clin Chim Acta; 1988 Apr 29; 173(3):313-6. PubMed ID: 3383431
    [Abstract] [Full Text] [Related]

  • 5. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C, Poignet JL, Mauras Y, Panthier G, Delons S, Allain P, Man NK.
    Trans Am Soc Artif Intern Organs; 1984 Apr 29; 30():479-82. PubMed ID: 6533925
    [No Abstract] [Full Text] [Related]

  • 6. Desferrioxamine induced aluminium removal in haemodialysis.
    Bonal J, Montoliu J, Löpez Pedret J, Bergadä E, Andrew L, Bachs M, Revert L.
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985 Apr 29; 21():366-70. PubMed ID: 3991524
    [Abstract] [Full Text] [Related]

  • 7. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA, Schmidt H, Scheuermann EH, Werner E, Kaltwasser JP, Schoeppe W.
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985 Apr 29; 21():382-6. PubMed ID: 3991527
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
    Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME.
    Nephrol Dial Transplant; 1992 Apr 29; 7(9):931-8. PubMed ID: 1328941
    [Abstract] [Full Text] [Related]

  • 9. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.
    Chang TM, Barre P.
    Lancet; 1983 Nov 05; 2(8358):1051-3. PubMed ID: 6138600
    [Abstract] [Full Text] [Related]

  • 10. Improvement of anaemia with desferrioxamine in haemodialysis patients.
    Praga M, Andrés A, de la Serna J, Ruilope LM, Nieto J, Estenoz J, Millet VG, Arnaiz F, Rodicio JL.
    Nephrol Dial Transplant; 1987 Nov 05; 2(4):243-7. PubMed ID: 3118265
    [Abstract] [Full Text] [Related]

  • 11. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD, D'Haese PC, Pires C, Lamberts LV, Simões J, De Broe ME.
    Nephrol Dial Transplant; 1996 Jan 05; 11(1):125-32. PubMed ID: 8649620
    [Abstract] [Full Text] [Related]

  • 12. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Barr J, Baillod RA.
    Arzneimittelforschung; 1994 Apr 05; 44(4):522-6. PubMed ID: 8011008
    [Abstract] [Full Text] [Related]

  • 13. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG, Acuña Aguerre G, Fernández Martín JL, Mouzo R, Cannata Andía JB.
    Nephrol Dial Transplant; 1994 Apr 05; 9(10):1431-4. PubMed ID: 7816256
    [Abstract] [Full Text] [Related]

  • 14. Estimation of statistical moments for desferrioxamine and its iron and aluminum chelates: contribution to optimisation of therapy in uremic patients.
    Andriani M, Nordio M, Saporiti E.
    Nephron; 1996 Apr 05; 72(2):218-24. PubMed ID: 8684530
    [Abstract] [Full Text] [Related]

  • 15. Ultrafiltrable aluminium after very low doses of desferrioxamine.
    Canteros A, Díaz-Corte C, Fernández-Martín JL, Gago E, Fernández-Merayo C, Cannata J.
    Nephrol Dial Transplant; 1998 Jun 05; 13(6):1538-42. PubMed ID: 9641189
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M, Sipilä R, Pitkänen E.
    Scand J Urol Nephrol Suppl; 1990 Jun 05; 131():49-54. PubMed ID: 2075470
    [Abstract] [Full Text] [Related]

  • 19. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P, Day JP, Garstang FM, Hodge KC, Metcalfe PJ, Benzo Z, Hill K, Ralston AJ, Ball J, Denton J.
    Proc Eur Dial Transplant Assoc; 1983 Jun 05; 19():203-7. PubMed ID: 6878234
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.